TISIDB

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted, extracellular space, extracellular matrix.
Domain	PF00039 Fibronectin type I domain PF00040 Fibronectin type II domain PF00041 Fibronectin type III domain
Function	Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts.; FUNCTION: Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.

> Gene Ontology [ TOP ]
Biological Process	GO:0001525 angiogenesis GO:0001558 regulation of cell growth GO:0001704 formation of primary germ layer GO:0001706 endoderm formation GO:0001818 negative regulation of cytokine production GO:0002526 acute inflammatory response GO:0002576 platelet degranulation GO:0006887 exocytosis GO:0006929 substrate-dependent cell migration GO:0006931 substrate-dependent cell migration, cell attachment to substrate GO:0006953 acute-phase response GO:0007044 cell-substrate junction assembly GO:0007160 cell-matrix adhesion GO:0007161 calcium-independent cell-matrix adhesion GO:0007369 gastrulation GO:0007409 axonogenesis GO:0007492 endoderm development GO:0008360 regulation of cell shape GO:0008361 regulation of cell size GO:0009306 protein secretion GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0010952 positive regulation of peptidase activity GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0016049 cell growth GO:0018149 peptide cross-linking GO:0022604 regulation of cell morphogenesis GO:0022617 extracellular matrix disassembly GO:0030198 extracellular matrix organization GO:0030307 positive regulation of cell growth GO:0030335 positive regulation of cell migration GO:0030516 regulation of axon extension GO:0031346 positive regulation of cell projection organization GO:0031589 cell-substrate adhesion GO:0032535 regulation of cellular component size GO:0033622 integrin activation GO:0034329 cell junction assembly GO:0034330 cell junction organization GO:0034446 substrate adhesion-dependent cell spreading GO:0035987 endodermal cell differentiation GO:0038044 transforming growth factor-beta secretion GO:0040017 positive regulation of locomotion GO:0043062 extracellular structure organization GO:0045055 regulated exocytosis GO:0045666 positive regulation of neuron differentiation GO:0045773 positive regulation of axon extension GO:0045785 positive regulation of cell adhesion GO:0045862 positive regulation of proteolysis GO:0045927 positive regulation of growth GO:0048144 fibroblast proliferation GO:0048145 regulation of fibroblast proliferation GO:0048146 positive regulation of fibroblast proliferation GO:0048514 blood vessel morphogenesis GO:0048588 developmental cell growth GO:0048638 regulation of developmental growth GO:0048639 positive regulation of developmental growth GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048675 axon extension GO:0050663 cytokine secretion GO:0050707 regulation of cytokine secretion GO:0050708 regulation of protein secretion GO:0050709 negative regulation of protein secretion GO:0050710 negative regulation of cytokine secretion GO:0050769 positive regulation of neurogenesis GO:0050770 regulation of axonogenesis GO:0050772 positive regulation of axonogenesis GO:0050900 leukocyte migration GO:0051048 negative regulation of secretion GO:0051051 negative regulation of transport GO:0051224 negative regulation of protein transport GO:0051272 positive regulation of cellular component movement GO:0051962 positive regulation of nervous system development GO:0052547 regulation of peptidase activity GO:0060560 developmental growth involved in morphogenesis GO:0061387 regulation of extent of cell growth GO:0061564 axon development GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0090066 regulation of anatomical structure size GO:1903531 negative regulation of secretion by cell GO:1904235 regulation of substrate-dependent cell migration, cell attachment to substrate GO:1904237 positive regulation of substrate-dependent cell migration, cell attachment to substrate GO:1904950 negative regulation of establishment of protein localization GO:1990138 neuron projection extension GO:2000147 positive regulation of cell motility GO:2001201 regulation of transforming growth factor-beta secretion GO:2001202 negative regulation of transforming growth factor-beta secretion
Molecular Function	GO:0002020 protease binding GO:0005178 integrin binding GO:0005518 collagen binding GO:0005539 glycosaminoglycan binding GO:0008047 enzyme activator activity GO:0008201 heparin binding GO:0016504 peptidase activator activity GO:0050839 cell adhesion molecule binding GO:0061134 peptidase regulator activity GO:1901681 sulfur compound binding
Cellular Component	GO:0005577 fibrinogen complex GO:0005578 proteinaceous extracellular matrix GO:0005604 basement membrane GO:0005605 basal lamina GO:0005793 endoplasmic reticulum-Golgi intermediate compartment GO:0016324 apical plasma membrane GO:0030141 secretory granule GO:0031091 platelet alpha granule GO:0031093 platelet alpha granule lumen GO:0031983 vesicle lumen GO:0034774 secretory granule lumen GO:0044420 extracellular matrix component GO:0045177 apical part of cell GO:0060205 cytoplasmic membrane-bounded vesicle lumen GO:0072562 blood microparticle GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04151 PI3K-Akt signaling pathway hsa04510 Focal adhesion hsa04512 ECM-receptor interaction hsa04810 Regulation of actin cytoskeleton
Reactome	R-HSA-170984: ARMS-mediated activation R-HSA-422475: Axon guidance R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1474244: Extracellular matrix organization R-HSA-2871796: FCERI mediated MAPK activation R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-1566977: Fibronectin matrix formation R-HSA-170968: Frs2-mediated activation R-HSA-179812: GRB2 events in EGFR signaling R-HSA-354194: GRB2 R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK R-HSA-109582: Hemostasis R-HSA-2428924: IGF1R signaling cascade R-HSA-112399: IRS-mediated signalling R-HSA-2428928: IRS-related events triggered by IGF1R R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-74751: Insulin receptor signalling cascade R-HSA-354192: Integrin alphaIIb beta3 signaling R-HSA-216083: Integrin cell surface interactions R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-5674135: MAP2K and MAPK activation R-HSA-5683057: MAPK family signaling cascades R-HSA-5684996: MAPK1/MAPK3 signaling R-HSA-375165: NCAM signaling for neurite out-growth R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-6802957: Oncogenic MAPK signaling R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF R-HSA-76009: Platelet Aggregation (Plug Formation) R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-114608: Platelet degranulation R-HSA-169893: Prolonged ERK activation events R-HSA-5673001: RAF/MAP kinase cascade R-HSA-8853659: RET signaling R-HSA-76005: Response to elevated platelet cytosolic Ca2+ R-HSA-180336: SHC1 events in EGFR signaling R-HSA-112412: SOS-mediated signalling R-HSA-162582: Signal Transduction R-HSA-6802952: Signaling by BRAF and RAF fusions R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-74752: Signaling by Insulin receptor R-HSA-449147: Signaling by Interleukins R-HSA-2586552: Signaling by Leptin R-HSA-186797: Signaling by PDGF R-HSA-6802949: Signaling by RAS mutants R-HSA-1433557: Signaling by SCF-KIT R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-194138: Signaling by VEGF R-HSA-6802948: Signaling by high-kinase activity BRAF mutants R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants R-HSA-166520: Signalling by NGF R-HSA-187687: Signalling to ERKs R-HSA-167044: Signalling to RAS R-HSA-187706: Signalling to p38 via RIT and RIN R-HSA-4420097: VEGFA-VEGFR2 Pathway R-HSA-5218921: VEGFR2 mediated cell proliferation R-HSA-372708: p130Cas linkage to MAPK signaling for integrins

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04810 Regulation of actin cytoskeleton

Reactome

R-HSA-170984: ARMS-mediated activation
R-HSA-422475: Axon guidance
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1474244: Extracellular matrix organization
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-1566977: Fibronectin matrix formation
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-354194: GRB2
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-109582: Hemostasis
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-354192: Integrin alphaIIb beta3 signaling
R-HSA-216083: Integrin cell surface interactions
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-5674135: MAP2K and MAPK activation
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-6802957: Oncogenic MAPK signaling
R-HSA-6802955: Paradoxical activation of RAF signaling by kinase inactive BRAF
R-HSA-76009: Platelet Aggregation (Plug Formation)
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-169893: Prolonged ERK activation events
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-6802952: Signaling by BRAF and RAF fusions
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-6802949: Signaling by RAS mutants
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-6802948: Signaling by high-kinase activity BRAF mutants
R-HSA-6802946: Signaling by moderate kinase activity BRAF mutants
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
R-HSA-372708: p130Cas linkage to MAPK signaling for integrins

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FN1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29655625	colon carcinoma	Promote immunity	This technology was used for vaccination against a marker of the tumor vasculature, the well-known extra domain B (EDB) of fibronectin.

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FN1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.549	0.387
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.69	0.852
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.446	0.87
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.939	0.163
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.021	0.784
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.823	0.871
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.484	0.589
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.584	0.843
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.417	0.897
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.337	0.909
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.575	0.895
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.219	0.379

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FN1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	2.7	8.4	0.12
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	3.4	7.7	0.176
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	18.2	-18.2	0.199
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	7.7	1.4	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FN1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FN1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FN1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FN1
Name	fibronectin 1
Aliases	CIG; LETS; GFND2; FINC; migration-stimulating factor; cold-insoluble globulin; ED-B; FN; FNZ; GFND; Fibronec ......
Chromosomal Location	2q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FN1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting FN1.

ID	Name	Drug Type	Targets	#Targets
DB01593	Zinc	Small Molecule	A1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......	119
DB06245	Lanoteplase	Biotech	ANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......	17
DB08888	Ocriplasmin	Biotech	A2M, FN1, SERPINF2	3

Browse FN1